Oncology Drug Pipeline Analysis – Regional Analysis
On the basis of region, the global oncology drug pipeline analysis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate in terms of growth in oncology drug pipeline market. According to the 2015 annual report of the American Cancer Society, although cancer-related death rate in the U.S. have reduced, cancer still remains the second most common cause of death in the country. Therefore, such high prevalence of cancer is expected to drive growth of the oncology drug pipeline market in North America.
Asia Pacific is expected to witness significant growth in the global oncology drug pipeline analysis market. This is owing to increasing prevalence of various kind of cancers in the region, especially in emerging economies such as China and India.
Furthermore, key players are focused on establishing manufacturing facility in Asia Pacific. For instance, in September 2018, BeiGene Co.Ltd. —a commercial-stage biotechnology company, selected GE Healthcare’s bio manufacturing facility— KUBio, for large-scale production of its cancer monoclonal antibodies in China.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients